Saphenous sparing treatments and reuse of saphenous veins. How, When, Where, Why

Invitation letter

S Ricci¹

¹Private practice Centro Medico Parioli, Roma, Italia

submitted: Oct 10, 2022, accepted: Oct 22, 2022, EPub Ahead of Print: Oct 28, 2022, published: Apr 30, 2023 Conflict of interest: None

DOI: 10.24019/jtavr.141 - Corresponding author: Prof. Stefano Ricci, varicci@tiscali.it

© 2023 Fondazione Vasculab impresa sociale ONLUS. All rights reserved.

Dear Colleagues and Friends,

Reading the literature in phlebological magazines, it seems as if most experts of Chronic venous insufficiency consider the Great Saphenous Vein (GSV) as an organ without any utility and, even more, the cause of the disease.

However, although involved by the reflux passage, GSV is not cause of the pathology. Historically, it has been easier to strip it (or to cook it, to shrink it, to glue it, to freeze it) instead of trying to heal it. The thorough study of hemodynamics by Doppler and Duplex changed the perspective over the GSV, i.e. it changed from being the cause of the incompetence to become the main way for the reflux to run out.

I was invited by the Chief Editor of JTAVR (Journal of Theoretical and Applied Vascular Research) to plan the Project "Saphenous sparing treatments and reuse of saphenous veins. How, When, Where, Why.", combining different points of view about "Saphenous sparing", which is a controversial topic, but it is as well so actively sustained by several Authors.

I invite You to participate with a contribute of your own and of your collaborators (a short review, an original article, a clinical case, a commented image).

In case You write a short review, You could comply with my (not strict) editorial suggestion, following these non-mandatory basic points:

- How (strategy and technical method to achieve saphenous sparing)
- When (in which cases the goal is possible/impossible/inappropriate)
- Where (in hospital or in office; privately or in the public service)
- Why (the rationale and the importance of sparing)
- What for (substitute as a bypass or anything else)
- How the patient should be informed
- What then (expected results, 2- 5 years outcome, recurrences, solutions)

The technical details of your participation will be included in an accompanying message of the JTAVR Secretariat.

I hope You will participate to this JTAVR Project and, together with the JTAVR editorial team, I am looking forward to receive your confirming answer.

My best regards

Prof. Stefano Ricci

Project Editor

"Saphenous sparing treatments and reuse of saphenous veins" JTAVR Project $\,$

